REM Sleep Behavior Disorder (RBD) is a disorder in which people talk or move during their dreaming sleep. People with RBD have higher risk of developing a neurological disorder, such as Parkinson’s disease, dementia with Lewy bodies, or multiple system atrophy. This group of disorders – termed synucleinopathies – is our research focus. The main goal of NAPS is to develop neuroprotective treatments to delay or prevent synucleinopathies.

  • Do you act out your dreams? Are you living with RBD?

    Do you act out your dreams? Have you been diagnosed with REM Sleep Behavior Disorder? Explore resources and opportunities to participate in research.

    RBD Resources

  • Are you a scientist or industry partner?

    Learn more about REM Sleep Behavior Disorder and explore active areas of research and potential collaboration in synucleinopathies.

    Resources for Researchers

  • REMEDY | REM Sleep Behavior Disorder Education Delivery

    REMEDY is an educational portal offering information on RBD, clinical studies, research opportunities, and resources for patients, loved ones, physicians, and researchers.

    Explore Our Educational Portal
 

Join the RBD Registry

The NAPS Consortium on REM Sleep Behavior Disorder (RBD) has established a registry for individuals living with RBD, partners and family of someone diagnosed with RBD, and those wanting to learn more about RBD.

This information is used to identify study participants, assist care teams providing care to individuals with RBD and to study RBD treatments and outcomes.

 

Your privacy is important to us. All personal health information (PHI) is protected and stored in a HIPAA compliant system.

3rd Annual Industry Roundtable

Join us for the 3rd Annual Industry Roundtable hosted by the North American Prodromal Synucleinopathy (NAPS) Consortium for RBD during the International Congress of Parkinson’s Disease and Movement Disorders® Meeting.

Date: Monday, October 6, 2025
Time: 4 p.m. - 6 p.m.
Location: Venue near the Honolulu Convention Center (TBA)

This exclusive session invites representatives from pharma and biotech to connect with NAPS leadership. Explore collaboration opportunities, share advancements in early detection and phenoconversion risk stratification, and discuss neuroprotective clinical trial designs.

RSVP required due to limited space. Contact us at info@naps-rbd.org for more information or to request an invitation.

Recent RBD News

RBD in the News
Hearing Loss, Incident Parkinson Disease, and Treatment With Hearing Aids
Hearing Loss, Incident Parkinson Disease, and Treatment With Hearing Aids

A groundbreaking study published in JAMA Neurology, led by Dr. Lee Neilson, a NAPS investigator at Oregon Health Sciences University, explores the connection between hearing loss and Parkinson's disease (PD) risk in over 3 million US veterans.

Read More →
Driving Meaningful Progress in Neurodegenerative Disease Research at SLEEP 2025
Driving Meaningful Progress in Neurodegenerative Disease Research at SLEEP 2025

In early June, the American Academy of Sleep Medicine hosted the 39th Annual Meeting of the Associated Professional Sleep Societies, LLC (APSS), a joint event between the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS).

For nearly 40 years, the SLEEP annual meeting has been the leading networking event for sleep professionals across the globe. This year, SLEEP 2025 took place in Seattle, Washington, drawing global experts in sleep medicine and research, with several NAPS investigators and support teams contributing to the event's discussions.

Read More →
Tracking DLB Symptoms Before Diagnosis: Are Men and Women Different?
Tracking DLB Symptoms Before Diagnosis: Are Men and Women Different?

Dr. Tanis Ferman, a NAPS Clinical Core investigator, co-authored a study exploring how dementia with Lewy bodies (DLB) symptoms differ between men and women in the two years before diagnosis.

Read More →
Unlocking Brain Health: New Study Explores Breakthrough MRI Technique for Early Parkinson’s Detection
Unlocking Brain Health: New Study Explores Breakthrough MRI Technique for Early Parkinson’s Detection

New research from France highlights a promising brain scan technique – neuromelanin-sensitive MRI – that measures dopamine in a key brain region affected by Parkinson’s disease (PD).

Read More →
New Global Consensus on RBD Treatment: What You Need to Know
New Global Consensus on RBD Treatment: What You Need to Know

Explore the latest consensus on managing RBD, led by NAPS Investigator Dr. Aleksandar Videnovic and the International RBD study group.

Read More →
2025 International RBD Study Group Meeting
2025 International RBD Study Group Meeting

NAPS Consortium members took center stage, presenting on key topics and leading discussions on neurophysiology, RBD ethics, longitudinal data, and patient risk communication, just to name a few.

Read More →